BVA guided treatment in heart failure has been shown to significantly improve multiple measures of patient outcomes including a reduction in 30-day mortality by 82%, 1-year mortality by 86%, 30-day readmissions by 56% and when BVA is done on admission, results in a 2.1 day length of stay.
Hospitals and clinicians struggle with readmissions, mortality and wasted resources. The BVA-100 test provides clinicians with accurate, actionable data to optimize treatment plans and individualize care, improving outcomes and reducing duration and cost of care.
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.
Kathryn A. Kornafel | Vice President, Marketing & Commercial Development
107 Meco Lane
Oak Ridge, TN 37830
Direct Measurement of Total Blood, Plasma, and Red Cell Volume
Guides Fluid Management
Differentiates Between True and Dilutional Anemia